Highlights Passage Bio, Inc.

Equities

PASG

US7027121000

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
1.48 ^USD	+0.68%		+4.96%	+46.53%

03-04	Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-04	Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-04	CI
Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	12-20	CI
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study	07/08/23	CI
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	06/03/23	CI
Passage Bio, Inc. Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023	24/02/23	CI
Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study	14/12/22	CI
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Earnings Flash (PASG) PASSAGE BIO Reports Q3 Loss $-0.49, vs. Street Est of $-0.77	10/11/22	MT
Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations	11/08/22	CI
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy	08/06/22	CI
Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting	18/05/22	CI
Earnings Flash (PASG) PASSAGE BIO Reports Q1 Loss $-0.79, vs. Street Est of $-0.92	16/05/22	MT
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease	29/03/22	CI
Passage Bio, Inc. Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease	10/03/22	CI
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	03/03/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Passage Bio, Inc.

Equities

PASG

US7027121000

Highlights

Filters